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BACKGROUND: Major depressive disorder (MDD) is the second largest cause of global disease burden. It has an
estimated heritability of 37%, but published genome-wide association studies have so far identiﬁed few risk loci.
Haplotype-block-based regional heritability mapping (HRHM) estimates the localized genetic variance explained by
common variants within haplotype blocks, integrating the effects of multiple variants, and may be more powerful for
identifying MDD-associated genomic regions.
METHODS: We applied HRHM to Generation Scotland: The Scottish Family Health Study, a large family- and
population-based Scottish cohort (N 5 19,896). Single-single nucleotide polymorphism (SNP) and haplotype-based
association tests were used to localize the association signal within the regions identiﬁed by HRHM. Functional
prediction was used to investigate the effect of MDD-associated SNPs within the regions.
RESULTS: A haplotype block across a 24-kb region within the TOX2 gene reached genome-wide signiﬁcance in
HRHM. Single-SNP- and haplotype-based association tests demonstrated that ﬁve of nine genotyped SNPs and two
haplotypes within this block were signiﬁcantly associated with MDD. The expression of TOX2 and a brain-speciﬁc
long noncoding RNA RP1-269M15.3 in frontal cortex and nucleus accumbens basal ganglia, respectively, were
signiﬁcantly regulated by MDD-associated SNPs within this region. Both the regional heritability and single-SNP
associations within this block were replicated in the UK–Ireland group of the most recent release of the Psychiatric
Genomics Consortium (PGC), the PGC2–MDD (Major Depression Dataset). The SNP association was also replicated
in a depressive symptom sample that shares some individuals with the PGC2–MDD.
CONCLUSIONS: This study highlights the value of HRHM for MDD and provides an important target within TOX2 for
further functional studies.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2016.12.012Major depressive disorder (MDD) is ranked as the second
leading contributor to the global disease burden in terms of
years lived with disability (1). The narrow sense heritability of
MDD has been estimated to be 37% by twin studies (2),
suggesting a substantial contribution from genetic factors. In
efforts to identify speciﬁc genetic risk factors for MDD, family-
based linkage studies have identiﬁed several signiﬁcant peaks
in certain families, but the ﬁndings have been inconsistent (3).
Genome-wide association studies (GWASs) of unrelated
participants have successfully identiﬁed hundreds of loci& 2017 Society of Biological Psychiatry. This is an open access a
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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SEE COMMENTAassociated with other psychiatric disorders (4), but for MDD
only four genome-wide signiﬁcant and replicable loci have
been identiﬁed by two large GWASs: one on a reﬁned MDD
phenotype for Chinese women and one on self-report-based
depression using less intensive phenotyping in a much larger
European sample (5–7).
Several factors may be responsible for the comparatively
sparse GWAS results in MDD. First, MDD is likely to have a
highly polygenic genetic architecture where the disease risk
is conferred by many causal variants of small effect (8,9).rticle under the
nal ISSN: 0006-3223
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PsychiatryCombined with the high prevalence of MDD (10) and the
possible incomplete linkage disequilibrium (LD) between gen-
otyped single nucleotide polymorphisms (SNPs) and causal
SNPs, single-SNP-based genome-wide association tests may
have insufﬁcient power to detect individual causal variants
(11). Second, clinical heterogeneity has been shown in MDD
between populations (6,12), and this may lead to difﬁculties in
identifying causal variants across cohorts (13). Whereas
GWAS sample sizes for MDD are increasing and efforts to
reﬁne the MDD phenotype are in progress (5,7), alternative
methodologies for detecting the signal arising from causal
variants within and across families may also be productive.
Regional heritability mapping (RHM) is a method used to
identify small genomic regions accounting for a signiﬁcant
proportion of the phenotypic variance in a trait of interest (14).
In contrast to single-SNP-based tests, RHM integrates effects
from multiple SNPs by using a regional genetic relationship
matrix estimated from SNPs within a region. The matrix is
constructed for each region deﬁned by a sliding window
across the genome and is then used to estimate the variance
explained by the variants within the region in a linear mixed
model (14). The major advantage of RHM is that the regional
genetic relationship matrices not only tag the effect of
genotyped variants but also measure the effect of ungeno-
typed and rare variants, including those associated with the
SNPs but with individual effects too small to be detected by
GWASs (14,15). Previous studies have shown that RHM has
greater power to detect rare variants and multiple alleles in
regions where GWASs provided null ﬁndings (15–17). In 2014,
Shirali et al. developed a haplotype-block-based RHM (HRHM)
method as an improved version of RHM. HRHM uses hap-
lotype blocks as the unit of mapping; therefore, the identiﬁed
blocks have less complex local LD structures (18).
In this study, we applied HRHM to a homogeneous sample
of approximately 20,000 Scottish participants containing both
closely and distantly related subjects with genome-wide
genotyping data and a standardized structured clinical MDD
diagnosis (19). We sought to identify genomic regions confer-
ring risk for MDD, which were then further explored using
single-SNP- and haplotype-based association tests. We then
examined the functional effects of the MDD-associated SNPs
within the identiﬁed block. Finally, replication analyses were
performed in independent samples for both the regional
heritability and SNP association results.METHODS AND MATERIALS
The Tayside Research Ethics Committee (reference 05/S1401/
89) provided ethical approval for the study. Participants all
gave written consent after having an opportunity to discuss
the project and before any data or samples were collected.
Datasets
Discovery Sample: Generation Scotland: The Scot-
tish Family Health Study. Generation Scotland: The Scot-
tish Family Health Study (GS:SFHS) contains 21,387 subjects
(nmale 5 8772, nfemale 5 12,615; agemean 5 47.2 years,
SD 5 15.1) who were recruited from the registers of collab-
orating general practices in Glasgow, Tayside, Ayrshire, Arran,Biological Psychand Northeast regions of Scotland, United Kingdom. At least
one ﬁrst-degree relative aged 18 years or over was required to
be identiﬁed for each participant (19,20). A structured clinical
interview was used for the diagnosis of lifetime DSM-IV mood
disorders (21,22). Details of MDD diagnosis, genotyping,
quality control, and imputation methods are described in the
Supplement. In total, 561,125 genotyped and 8,642,105 post-
imputation autosomal SNPs that passed quality control criteria
were available for 19,896 participants (2659 MDD cases and
17,237 control subjects) for subsequent analyses.
Replication Sample 1: UK Biobank. Data used in this
study were provided as part of the UK Biobank project (reference
no. 4844). Details for genotyping, quality control, imputation, and
phenotyping are described in the Supplement. In brief, genotyping
data were available for 152,729 UK Biobank participants recruited
in the United Kingdom (23). The probable MDD phenotype was
created based on the putative MDD deﬁnition established in Smith
et al. using responses to a touchscreen questionnaire (24), from
self-report information, and from inpatient records via linkage to
hospital episode data (see Supplement). After quality control and
removing subjects who were in both the GS:SFHS and UK
Biobank datasets, and one of each pair of close relatives (related-
ness.0.05) of GS:SFHS participants or the remaining UK Biobank
participants, 1,198,327 SNPs for 24,015 subjects with the putative
MDD phenotype available (8143 cases and 15,872 control sub-
jects) remained in downstream analyses.
Replication Sample 2: Psychiatric Genomics Consor-
tium Major Depression Dataset. The Psychiatric Genomics
Consortium (PGC) provided individual genotypes (best guess) of
imputed SNPs for participants from 22 cohorts in the PGC Major
Depression Dataset (PGC2–MDD) (Supplemental Table S1). All
cases met DSM-IV criteria for life MDD; the majority of them were
ascertained clinically. Most control samples were screened, and
participants with lifetime MDD were removed (Supplemental Table
S1). Details for genotyping, quality control, imputation, and
phenotyping are described in the Supplement. After quality control
and removing subjects who overlapped with the GS:SFHS and UK
Biobank datasets, 32,554 subjects of European ancestry (13,261
cases and 19,293 control subjects) were used in downstream
analysis. Consistent with earlier work (25,26), we grouped the 22
cohorts into 7 groups based on the country of ancestor information
for regional heritability analysis (Supplemental Table S1).
Replication Sample 3: Depressive Symptom Data-
sets. The depressive symptom (DS) sample contains overlapping
individuals with replication samples 1 and 2. Okbay et al. carried
out a GWAS meta-analysis (N 5 180,866) on three samples using
depressive symptoms as the trait of interest (27). The ascertained
MDD diagnosis information was available for two samples: PGC1–
MDD (ncases 5 9240, ncontrols 5 9519) and the Resource for
Genetic Epidemiology Research on Aging (ncases 5 7231, ncontrols
5 49,316) (27). For the third sample, UK Biobank (N 5 105,739), a
continuous phenotype measuring the severity of depressive
symptom had been created and used in the meta-analysis (27).
Although this sample overlapped with the PGC2–MDD and UK
Biobank samples, it provided results based on a nondiagnostic
quantitative measure of depressive symptoms and involvediatry September 1, 2017; 82:312–321 www.sobp.org/journal 313
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Research on Aging (27).
Genome-wide HRHM
RHM is a method for detecting localized genomic regions
where genetic variants contribute signiﬁcantly to the variation
of phenotype of interest (14). As an improved version of RHM,
HRHM divides the genome into haplotype blocks based on the
recombination hotspots in the genome (18). Details of HRHM
are described in the Supplement. In brief, in GS:SFHS, the
genotyped SNPs were mapped to 49,637 haplotype blocks
across the genome and the regional heritability was estimated
and tested for each of the haplotype blocks. A standard “two-
GRM” model incorporates two genomic relationship matrices
(GRMs): a regional genomic relationship matrix (rGRM) esti-
mated from SNPs in the haplotype block and a complement
genomic relationship matrix (cGRM) estimated from all SNPs
that are not included in the haplotype block. These GRMs
were jointly ﬁtted as random effects in linear mixed models.
Covariates ﬁtted as ﬁxed effects include age, age2, sex, and
20 principal components. A log likelihood ratio test (LRT) is
applied to test the signiﬁcance of random effect represented in
an rGRM by comparing a model with both a cGRM and an
rGRM ﬁtted against a model including the cGRM but without
an rGRM ﬁtted. The genome-wide signiﬁcance threshold for
p values from the LRT is 1.01 3 10–6 (NBonferroni 5 49,637).
This two-GRM model, while providing an unbiased estimate of
regional heritability, was highly computationally demanding.
To improve the calculation efﬁciency, a preadjustment strategy
was applied in the genome-wide HRHM (see Supplement). For
haplotype blocks that exceeded the genome-wide signiﬁcant
threshold, we retested the block using the two-GRM model to
provide an accurate estimation of regional heritability in the
target block. All the analyses were performed in REACTA
(14,28). According to the GCTA-GREML Power Calculator, this
study is well powered for the genomic-relatedness-based
restricted maximum-likelihood-based SNP heritability analysis
(99.88%) (29).
Localized Association Tests for the Signiﬁcant
Haplotype Block Identiﬁed by HRHM in GS:SFHS
HRHM identiﬁed a signiﬁcant block chr20:42555671–
42579473, and we performed a series of association tests to
localize the association signals within this block in GS:SFHS.
Single-SNP-Based Association Test for Common
SNPs Within the Identiﬁed Haplotype Block. Associa-
tion tests were performed on genotyped and imputed com-
mon SNPs located in the signiﬁcant haplotype block
chr20:42555671–42579473 using GCTA–MLMA (mixed linear
model-based association analysis) (30). The SNP effect was
tested as a ﬁxed effect; other covariates included age, age2,
sex, and 20 principal components. To prevent the estimates of
SNP effects from being confounded by the polygenic compo-
nent and family structure, cGRM and cGRMkin were ﬁtted
simultaneously as random effects in the model (31). cGRM
(complement-SNP-set GRM) was the genomic relationship
created matrix using all of the genotyped SNPs, excluding314 Biological Psychiatry September 1, 2017; 82:312–321 www.sobp.the SNPs in the hit block; cGRMkin was the kinship relationship
matrix (representing pedigree-associated genetic variation).
cGRMkin was created by setting elements in cGRM that were
less than or equal to 0.05 to 0 (31). The estimated ﬁxed
effect (on the linear scale) was transformed to logit and liability
scale using Taylor series approximation (32). Bonferroni
multiple testing correction was performed for the p values for
each SNP.
Single-Haplotype-Based Association Test. Single-
haplotype-based association tests were performed for the
common haplotypes (frequency $ 0.01) derived from the nine
genotyped common SNPs located in the signiﬁcant haplotype
block chr20:42555671–42579473 using GCTA–MLMA (30) for the
full dataset and an unrelated dataset and using famLBL (family-
triad-based logistic Bayesian Lasso) (33) for a subset consisting
of case–parent trios in GS:SFHS. Details of the single-haplotype-
based association test are described in the Supplement.
Functional Effects of MDD-Associated SNPs in the
Signiﬁcant Block
The signiﬁcant haplotype block chr20:42555671–42579473 is
located in the intron region and a proportion of an adjacent
exon of gene TOX2. To investigate the potential functional
effects from variants within this block, we imputed the nine
genotyped SNPs within this block to 53 common SNPs based
on Haplotype Reference Consortium reference; all of them are
noncoding SNPs. We performed the single-SNP-based asso-
ciation test for each of them with MDD using GCTA–MLMA
(the same method for genotyped SNPs). This identiﬁed 38
imputed SNPs signiﬁcantly associated with MDD. We then
examined the functional role of the 38 SNPs using the
following functional annotation tools and analyses: the poten-
tial to affect the binding of transcription factors in Regulo-
meDB (34), Genome Wide Annotation of Variants (GWAVA),
Genomic Evolutionary Rate Proﬁling (GERP) (35), brain-tissue-
speciﬁc allelic effect on gene expression (expression quanti-
tative trait loci [eQTL] analysis) based on GTEx and BRAINEAC
databases, and brain-tissue-speciﬁc allelic effect on DNA
methylation in CpG loci (methylation quantitative trait loci
[meQTL] analysis). Details of these tools and analyses are
described in the Supplement.
Replication Analysis
Regional Heritability in the Signiﬁcant Block Identi-
ﬁed in GS:SFHS. Individual genotypes in UK Biobank and
PGC2–MDD (22 cohorts) were used to estimate the regional
heritability of the target haplotype block in the two samples.
The two-GRM model (rGRM 1 cGRM) was applied to provide
accurate estimates. For PGC2–MDD, the regional heritability
was estimated for each of the 7 groups deﬁned based on
country of ancestor (Supplemental Table S1) as well as for the
combined dataset.
Single-SNP-Based Association Test for the Five Sig-
niﬁcant SNPs (Genotyped) Within the Signiﬁcant
Block Identiﬁed in GS:SFHS. For UK Biobank, the
single-SNP-based association tests were performed using aorg/journal
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center, batch, and 15 principal components provided by UK
Biobank. For PGC2–MDD, the association test was performed
using a logistic model for each individual cohort. Covariates
include sex and 20 principal components (the age variable was
not yet available for the full dataset at the time of this study).
Meta-analysis was performed across all cohorts in each group
to generate group-level association statistics. The meta-
analysis was performed using the “metagen” function in the
R package “meta”. For the DS sample the GWAS summary
statistics were downloaded from the website of the Social
Science Genetic Association Consortium (http://www.the
ssgac.org/#!data/kuzq8).RESULTS
Genome-wide HRHM was carried out for 49,637 haplotype blocks
using 561,125 genotyped common SNPs in GS:SFHS for MDD
(ncase5 2659, ncontrol5 17,237). The regional heritability from each
haplotype block was tested using a preadjusted GRM strategy in
the linear mixed model. The Manhattan plot and quantile-quantile
plot for the LRT are shown in Figure 1. One haplotype block
covering a 24-kb region in the intron region and a proportion of an
adjacent exon of gene TOX2 exceeded the genome-wide signiﬁ-
cant threshold (pBonf_threshold 5 1.01 3 10
–6): hg19:chromo-
some20:42555671–42579473 (plrt 5 8.86 3 10
–7) (Figure 1). The
two-GRM model conﬁrmed the signiﬁcance of this haplotype
block (plrt 5 5.6 3 10
–7), and the regional heritability (h2g) was
estimated to be 0.008 (0.006). The regional heritability of this block
was more signiﬁcant in female MDD (h2g 5 0.009, SE 5 0.007,
plrt 5 5.64 3 10
–5, ncase 5 1893, ncontrol 5 9818) than in male
MDD (h2g 5 0.003, SE 5 0.004, plrt 5 .02, ncase 5 765,
ncontrol 5 7420).
We further performed a series of association tests to
disentangle the signal detected by HRHM in the signiﬁcant
block. Using the single-SNP-based association test, ﬁve of the
nine genotyped common SNPs within the hit block were
signiﬁcantly associated with MDD (Table 1 and Supplemental
Table S2). The ﬁve signiﬁcant SNPs were in high LD with each
other (Figure 1D), and their minor alleles showed a consistent
negative effect on the risk of MDD, with the odds ratio ranging
from 0.785 to 0.833 (Table 1). Haplotype-based association
tests for haplotypes derived from the nine SNPs showed that
two of the seven common haplotypes (frequency $ 0.01) were
associated with MDD. One of these haplotypes contains the
minor (protective) alleles of the ﬁve single-SNP-level signiﬁ-
cant SNPs, and one contains the major (risk) alleles. The size
and direction of the effects of the two haplotypes were
consistent with those estimated from the single-SNP-based
tests (odds ratio of 0.792 for the protective haplotype and
1.232 for the risk haplotype) (Table 2). Additional association
tests on subdatasets (unrelated and case–parent trio) showed
that the risk haplotype was signiﬁcantly associated with MDD
in the unrelated dataset (Supplemental Table S3), whereas the
protective haplotype was signiﬁcant in the case–parent trio
dataset (Supplemental Table S4).
The signiﬁcant block overlapped with an enhancer active in
multiple tissues and cell lines, including astrocytes (Figure 2A)
(37), and multiple alternative transcription start sites (TSSs)
including a TSS primarily expressed in the thalamus (the TSSBiological Psychlabeled as “p3@TOX2” in Figure 2A) (37), suggesting a
potential regulatory role. To link the association signal from
single variants with the potentially functional effects of those
variants on disease-relevant biological processes, we identi-
ﬁed 38 imputed SNPs in the target block signiﬁcantly asso-
ciated with MDD (Supplemental Table S5) and predicted their
potentially regulatory function using multiple predictors and
statistics of noncoding DNA function, including the likelihood
of affecting transcription factor binding, multiple genome-wide
properties, evolutionary conservation, and the cis effect on
gene expression of genes within a distance of 1 MB and on
DNA methylation. Among the 38 SNPs, 2 were annotated to
be “likely to affect TF binding” (score 5 2b) by RegulomeDB,
5 obtained a GWAVA–TSS score $ 0.5 (suggesting
“functional”), and 5 obtained a GERP score . 2 (suggesting
“constrained”) (Supplemental Table S6). Tissue-speciﬁc
SNP-cis-gene expression (cis-eQTL) analyses were performed
for the 38 SNPs using 11 brain tissues from GTEx and 10 brain
tissues from BRAINEAC. The results from GTEx showed that
the genotypes of 30 of the 38 SNPs signiﬁcantly stratify the
expression of gene RP1-269M15.3 (long noncoding RNA
[LncRNA]) in the tissue nucleus accumbens basal ganglia,
with the minor alleles signiﬁcantly upregulating the RNA
expression level (Supplemental Table S7) (Figure 2B). The
results from BRAINEAC suggested that all 38 SNPs signiﬁ-
cantly stratify the expression of gene TOX2 in the frontal
cortex (minor allele induces upregulation) (Figure 2C) and gene
C20orf62 (LncRNA) (minor allele induces downregulation) in
the cerebellar cortex (Supplemental Tables S8 and S9). The
results from meQTL analysis suggested that 30 of the 38
SNPs are signiﬁcant meQTL SNPs in the frontal cortex and
that particularly 19 of them signiﬁcantly stratify DNA methyl-
ation of a CpG locus cg24403644 (minor allele induces
hypomethylation) (Supplemental Table S10). The locus
cg24403644 is located in a cluster of TSSs in TOX2
(Figure 2) and shows differential methylation between human
fetal and postnatal lifetime in the frontal cortex and during
fetal brain development (38,39). Among signiﬁcant SNPs
in the cis-eQTL and cis-meQTL analyses, rs79645278 was
located in the peak of active enhancer (in astrocytes and
other cell lines) and was predicted to be “likely to affect TF
binding” (2b) in RegulomeDB, having a GWAVA–TSS score of
0.5 and a GERP score of 2.31 (Figure 2A–C and Supplemental
Table S6).
The regional heritability detected in the hit block was
replicated in the UK–Ireland group in PGC2–MDD with nominal
signiﬁcance (plrt 5 .049, h
2
g5 0.001, SE 5 0.001), whereas it
was not signiﬁcant in other groups in PGC2–MDD and UK
Biobank (Supplemental Table S11). The single-SNP-based
association test for the ﬁve signiﬁcant SNPs (genotyped) in
this block identiﬁed in GS:SFHS showed that all ﬁve were
replicated in the DS sample; all ﬁve were also replicated in the
UK–Ireland group in PGC2–MDD (Table 1). Results for indi-
vidual cohorts are shown in Supplemental Table S12 and
Supplemental Figure S1 but not in other PGC2–MDD groups
or in the meta-analyzed combined PGC2–MDD sample
(Supplemental Table S13); none of the ﬁve SNPs were
replicated in the UK Biobank sample, but all showed the same
consistent direction of effect as that reported in the discovery
sample (Table 1 and Supplemental Figure S1). Meta-analysisiatry September 1, 2017; 82:312–321 www.sobp.org/journal 315
Figure 1. Genome-wide haplotype-block-based regional heritability mapping results on major depressive disorder in Generation Scotland: The Scottish
Family Health Study (GS:SFHS). (A) Manhattan plot. Each point represents a haplotype block. The location of the point is the mid-position of the haplotype
block. (B) A quantile-quantile plot for the likelihood ratio test (LRT). The LRT statistics are distributed as a mixture of 0 and chi-squared (df 5 1) distribution.
(C) Zoom-in region of the hit haplotype block region in chromosome 20. (D) Linkage disequilibrium (LD) structure within the hit haplotype block in GS:SFHS.
The block is located in gene TOX2; it contains nine genotyped common SNPs (blue boxes), and ﬁve of them are in high LD (red arrows) in GS:SFHS.
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Psychiatryusing all independent UK–Ireland replication samples (UK
Biobank and four cohorts in PGC2–MDD and UK–Ireland)
showed that all ﬁve SNPs reached nominal signiﬁcance
(Supplemental Table S13), consistent sign with GS:SFHS as
shown in Figure 3, using SNP rs6093898 as an example.DISCUSSION
The current study used a combination of genome-wide
HRHM, localized association tests, and functional prediction
to identify candidate genomic regions associated with MDD.
Using the large Scottish cohort GS:SFHS, a genome-wide
signiﬁcant haplotype block located in gene TOX2 was identi-
ﬁed by HRHM as a risk region for MDD. Association tests
using both single SNPs and haplotypes within this block
highlighted candidates contributing genetic variants for
MDD. Replication analyses showed that the regional herit-
ability in this block was nominally signiﬁcant in the UK–Ireland
groups in PGC2–MDD. The SNP-level association signals
within the hit block were replicated in the UK–Ireland group
in PGC2–MDD and a study of DS that has overlapping
subjects from PGC2–MDD and UK Biobank.316 Biological Psychiatry September 1, 2017; 82:312–321 www.sobp.As shown in this study, compared with single-SNP-based
genome-wide association methods, HRHM provided the fol-
lowing advantages. First, a smaller number of tests were
performed; therefore, a less stringent threshold of genome-
wide signiﬁcance was applied. Second, haplotype blocks
rather than single SNPs were the unit of mapping; therefore,
these are relatively less dependent on the density of the
genotype arrays and do not require the same SNPs to be
typed or imputed in replication studies. Third, HRHM applied a
linear mixed model accounting for both polygenic component
and family structure, and it can be applied to both population
and family data. Fourth, because haplotype blocks were used
as the unit of mapping, the identiﬁed locus has a less complex
LD structure (Figure 1D), which will beneﬁt the downstream
identiﬁcation of candidate variants.
To date, published GWASs have mapped associated var-
iants to very few genes for MDD (LHPP, SIRT1, TMEM161B–
MEF2C, and NEGR1) (5,7). In this study, the identiﬁed haplotype
block was located in gene TOX2 (TOX high mobility group box
family member 2, also known as GCX1), indicating a new
candidate gene for MDD. TOX2 is a putative transcriptional
activator involved in the hypothalamo–pituitary–gonadalorg/journal
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Psychiatrysystem (40) and is located in a large genomic region that
has been previously reported as associated with depression
symptoms in psychotic illness (41,42). The same locus
has also been weakly associated with conduct disorder in a
previous study (43). Using available databases, we found
that convergent evidence from TSS by Fantom5 annotation
(Figure 2A), histone modiﬁcation markers and DNase peaks
representing active enhancers by ENCODE annotation
(Figure 2A), and transcription factor binding prediction by
RegulomeDB (Supplemental Table S6) suggested a regula-
tory function of this block. To test for the potential effects of
the variants within the block on gene expression, we per-
formed brain-tissue-speciﬁc cis-QTL analysis for SNPs sig-
niﬁcantly associated with MDD within the block. The
expression of an LncRNA RP1-269M15.3 was signiﬁcantly
upregulated by the minor alleles (minor alleles are protective
to MDD, as shown in Table 1 and Supplemental Table S5) of
candidate SNPs within the block in nucleus accumbens, a
tissue having been previously implicated in MDD (44). RP1-
269M15.3 was a multiexon LncRNA with a multispecies
conserved region (Supplemental Figure S2A) and was
expressed speciﬁcally only in brain tissues (Supplemental
Figure S2B) and therefore is of potential function in brain
tissues. Similarly, the expression of gene TOX2 was signiﬁ-
cantly upregulated by the minor alleles of candidate SNPs in
the frontal cortex, a relevant tissue of MDD as well (45). The
regulatory effect of MDD-associated SNPs in gene TOX2 in
the frontal cortex is further supported by the meQTL analysis
on the same tissue. Combined with the fact that all 19 SNPs
are both meQTL and eQTL SNPs for gene TOX2 in the frontal
cortex and the fact that hypomethylation has been previously
suggested to be correlated with up-regulation of gene expres-
sion (46), consistent evidence from both methylation and gene
expression data indicated that the minor alleles (protective) of
MDD-associated SNPs upregulate the gene expression of
TOX2 in the frontal cortex (Supplemental Tables S8 and S10).
Interestingly, the brain-speciﬁc expressions of both RP1-
269M15.3 and TOX2 were highly correlated (r $ .70) with
a number of depression-related genes (e.g., LRFN5, GRM7,
CRH) (47,48) in brain development (http://brainspan.org)
(Supplemental Tables S14 and S15), suggesting that the
expression networks involving those genes were potential
targets of the effects from candidate variants. These results
are consistent with a previous study suggesting an overrepre-
sentation of MDD GWAS signiﬁcant loci in central nervous
system expression and the regulation of gene expression in the
central nervous system during development (7).
The regional heritability in the identiﬁed block was nominally
signiﬁcant only in the UK–Ireland group of PGC2–MDD.
The ﬁve signiﬁcant genotyped SNPs within the block identiﬁed
in GS:SFHS were replicated in the DS sample and in the UK–
Ireland group in PGC2–MDD. The UK Biobank sample failed to
replicate any of them, although it showed a consistent sign of
effect. Those results are likely attributable to the phenotyping
differences [diagnosed MDD in GS:SFHS, mostly diagnosed
MDD in PGC (49), putative MDD in UK Biobank, and depres-
sive symptom in DS] and the clinical heterogeneity within MDD
across PGC2–MDD groups as shown in Supplemental
Table S10 (12). Notably, UK–Ireland, which shows the most
consistent replication results, is from the same country/regioniatry September 1, 2017; 82:312–321 www.sobp.org/journal 317
Table 2. Haplotype-Based Association Test Results for Common Haplotypes Derived From the Nine Genotyped Common
SNPs in GS:SFHS
Haplotype Frequency Beta (Linear) SE (Beta [Linear]) OR logOR SE (logOR) p Adjusted p
TAGCGACCT 0.120 0.026 0.005 1.232 0.209 0.058 2.47E-06 1.73E-05a
GGGTGGTCC 0.094 20.024 0.006 0.792 20.233 0.046 5.77E-05 4.04E-04a
TAGCAACCT 0.118 20.010 0.005 0.911 20.093 0.045 6.10E-02 4.27E-01
TAGCGACTC 0.311 0.006 0.004 1.052 0.051 0.035 1.24E-01 8.71E-01
GAGCAACCT 0.012 20.012 0.016 0.897 20.109 0.131 4.60E-01 1.00E100
TAGCAACCC 0.015 20.010 0.014 0.916 20.088 0.120 5.05E-01 1.00E100
TATCGACTC 0.304 20.002 0.004 0.980 20.020 0.033 5.59E-01 1.00E100
Adjusted p: Bonferroni method adjusted p values.
GS:SFHS, Generation Scotland: The Scottish Family Health Study; OR, odds ratio; SNP, single nucleotide polymorphism.
aSigniﬁcant results.
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Psychiatryas GS:SFHS, so its cohorts are likely to have a similar
local genomic recombination pattern and LD structure
with GS:SFHS and potentially carry alleles not common inFigure 2. Functional prediction of the hit haplotype block. (A) Functional annotation
and blue bars showing the genotype single nucleotide polymorphisms [SNPs] in Gen
intron region and a proportion of an adjacent exon of gene TOX2, overlapped with F
modiﬁcation peaks (H3K27Ac and H3K4Me1). Within the block, 38 imputed SNPs wer
as an example. This SNP is located in the peak of active enhancer in astrocyte (highligh
are both associated with MDD in GS:SFHS and gene expression, using SNP rs796452
of a long noncoding RNA RP1-269M15.3 in the tissue nucleus accumbens basal gangl
the frontal cortex (FCTX). CRBL, cerebellar cortex; eQTL, expression quantitative trait loc
occipital cortex (speciﬁcally primary visual cortex); PUTM, putamen; SNIG, substantia
318 Biological Psychiatry September 1, 2017; 82:312–321 www.sobp.other European cohorts, which may explain the better
replication result from this group (Figure 3 and Supplemental
Figure S1).of the hit block. The hit haplotype block (red bar on the left top showing the block
eration Scotland: The Scottish Family Health Study [GS:SFHS]) is located in the
antom5 enhancers and transcription start sites, and regulatory-relevant histone
e associated with major depressive disorder (MDD), using SNP rs79645278 (pink)
ted with blue line). (B, C) Boxplots showing tissue-speciﬁc effect from SNPs that
78 as an example. (B) The minor allele of rs79645278 upregulates the expression
ia. (C) The minor allele of rs79645278 upregulates the expression of gene TOX2 in
i; HIPP, hippocampus; MEDU, medulla (speciﬁcally inferior olivary nucleus); OCTX,
nigra; THAL, thalamus; TCTX, temporal cortex; WHMT, intralobular white matter.
org/journal
Figure 3. Forest plot showing meta-analysis for single-single
nucleotide polymorphism (SNP)-based association test on Generation
Scotland: The Scottish Family Health Study and all UK–Ireland replication
samples (four Psychiatric Genomics Consortium–Major Depression
Dataset [PGC2–MDD] cohorts and UK Biobank), using SNP rs6093898 as
an example. CI, conﬁdence interval; OR, odds ratio; seTE, standard error of
the estimate; TE, estimate of effect size; W, weight of individual studies.
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PsychiatryThere are, however, several limitations in the current study.
First, the readjustment strategy applied to genome-wide
HRHM; while it reduced the computational burden, it was
potentially excessively conservative in reporting true associa-
tions (observed LRT statistics were depleted from expectation,
as shown in Figure 1D), which consequently reduced the
power of HRHM (50). Second, phenotypic difference among
discovery and replication samples impeded the complete
replication of ﬁndings across all samples. UK Biobank samples
are also from the same country/region as GS:SFHS, as is the
UK–Ireland group of PGC2–MDD, but currently UK Biobank
samples have only putative MDD information available for a
small subset of genotyped participants. Ongoing clinical
assessment of MDD and the genotyping work on these
samples will potentially provide more power to the replication
analysis for our ﬁndings in future data releases.
Conclusions
The current study showed the ﬁrst application of genome-wide
HRHM to a psychiatric disorder. A genome-wide signiﬁcant
region was identiﬁed by HRHM, and the contributing
genetic effect was localized to variants and haplotypes within
the block. The results were partly replicated in two independ-
ent samples. Functional prediction and cis-eQTL analyses
suggested that the genotype of associated variants within
the block stratiﬁed the gene expression of a potentially
functional LncRNA RP1-269M15.3 and gene TOX2 in
MDD-relevant brain tissues, which should be explored in
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